Personalized cancer therapy for kids and teens
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests personalized cancer treatments for children and teens whose cancer has not responded to standard therapy. It uses information from precision medicine studies to match the right drug to each child's tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child's cancer (solid tumor, brain tumor, or lymphoma) has not responded to standard treatments, or no standard treatment exists.
- Your child is under 21 years old when starting the trial.
- Your child is already taking part in a precision medicine study (like PROFYLE or ZERO) that looks for genetic changes in their cancer.
- Your child has recovered from side effects of previous cancer treatments.
- Your child has adequate organ function (kidneys, liver, heart, etc.) and is able to follow the study schedule.
- Females who can become pregnant must have a negative pregnancy test, and males must agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This early-phase study tests whether a personalized cancer treatment plan based on your tumor’s test results can help people with aggressive cancers that are hard to treat. It may be an option if standard treatments didn’t work, aren’t possible for you, or you have few treatment choices.
This early-phase trial studies how safe and effective a combination of four medicines is for children and teens with certain solid tumors that have come back or cannot be controlled with standard treatment. It may help by improving tumor control, while also carefully tracking side effects.
Hear when a new Childhood Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.